Achillion Pharmaceuticals Reaches New 1-Year High at $8.68 (ACHN)
Shares of Achillion Pharmaceuticals (NASDAQ:ACHN) reached a new 52-week high during mid-day trading on Thursday , Stock Ratings News reports. The stock traded as high as $8.68 and last traded at $8.46, with a volume of 3,290,779 shares traded. The stock had previously closed at $7.92.
A number of analysts have recently weighed in on ACHN shares. Analysts at Piper Jaffray upgraded shares of Achillion Pharmaceuticals from a “neutral” rating to an “overweight” rating in a research note on Monday. They now have a $10.00 price target on the stock, up previously from $5.00. Separately, analysts at Wells Fargo & Co. upgraded shares of Achillion Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Monday. They now have a $10.00 price target on the stock, up previously from $7.36. Finally, analysts at JMP Securities upgraded shares of Achillion Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Friday, August 8th. They now have a $13.00 price target on the stock. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the company. Achillion Pharmaceuticals has an average rating of “Hold” and an average price target of $8.80.
The stock has a 50-day moving average of $7.23 and a 200-day moving average of $4.51. The company’s market cap is $825.3 million.
Achillion Pharmaceuticals (NASDAQ:ACHN) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.16) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.18) by $0.02. Analysts expect that Achillion Pharmaceuticals will post $-0.74 EPS for the current fiscal year.
Achillion Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases.
Receive News & Ratings for Achillion Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.